Prospective evaluation of community-acquired acute-phase hepatitis C virus infection.

PubWeight™: 3.06‹?› | Rank: Top 1%

🔗 View Article (PMID 15824985)

Published in Clin Infect Dis on March 03, 2005

Authors

Andrea L Cox1, Dale M Netski, Timothy Mosbruger, Susan G Sherman, Steffanie Strathdee, Danielle Ompad, David Vlahov, David Chien, Venkatakrishna Shyamala, Stuart C Ray, David L Thomas

Author Affiliations

1: Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. acox@jhmi.edu

Articles citing this

Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24

Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22

Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13

Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89

Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82

High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol (2008) 1.79

Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut (2015) 1.51

Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49

Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol (2007) 1.44

Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39

Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38

Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 1.33

Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 1.29

Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 1.18

Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology (2016) 1.12

Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res (2010) 1.10

Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J Mol Diagn (2011) 1.10

Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol (2013) 1.07

High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis (2011) 1.04

Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend (2010) 1.01

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99

A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. Hepatology (2013) 0.96

The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion (2010) 0.94

Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clin Infect Dis (2005) 0.93

Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis (2010) 0.92

Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92

Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology (2011) 0.92

Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. PLoS One (2014) 0.91

Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis (2011) 0.91

Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection. J Immunol (2012) 0.91

The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One (2011) 0.87

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One (2015) 0.87

Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol (2015) 0.86

The IFN-λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. Hepat Mon (2014) 0.86

Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis (2015) 0.85

Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol (2012) 0.85

Evolution of CD8+ T cell responses after acute PARV4 infection. J Virol (2013) 0.84

High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One (2013) 0.83

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol (2014) 0.82

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat (2015) 0.82

Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection. J Viral Hepat (2013) 0.81

Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil. BMC Infect Dis (2011) 0.80

The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques. Mol Ther (2013) 0.80

A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80

Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. J Virol (2015) 0.78

Differentially regulated gene expression associated with hepatitis C virus clearance. J Gen Virol (2012) 0.76

IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection. PLoS One (2013) 0.75

Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. Clin Infect Dis (2016) 0.75

CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS (2016) 0.75

Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol (2014) 0.75

Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC(3) Study. J Viral Hepat (2016) 0.75

Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog (2017) 0.75

Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat (2015) 0.75

The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia. Virol J (2016) 0.75

Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun (2017) 0.75

Natural evolution of hepatitis C virus infection in hemodialysis Tunisian patients and CTLA-4 SNP's. World J Gastroenterol (2015) 0.75

New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology. ScientificWorldJournal (2013) 0.75

Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. J Infect Dis (2016) 0.75

Evaluation of operational chronic infection endpoints for HCV vaccine trials. Contemp Clin Trials (2008) 0.75

Favorable Socioeconomic Status and Recreational Polydrug Use Are Linked With Sexual Hepatitis C Virus Transmission Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men. Open Forum Infect Dis (2016) 0.75

Articles by these authors

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62

A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18

Psychological sequelae of the September 11 terrorist attacks in New York City. N Engl J Med (2002) 10.07

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22

Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58

Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis (2012) 7.53

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13

Protection against persistence of hepatitis C. Lancet (2002) 5.94

Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79

Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse (2002) 5.65

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS (2005) 5.43

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol (2006) 5.41

The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21

Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06

APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54

Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (2003) 4.25

The epidemiology of post-traumatic stress disorder after disasters. Epidemiol Rev (2005) 4.09

Television images and psychological symptoms after the September 11 terrorist attacks. Psychiatry (2002) 4.07

Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol (2003) 3.93

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health (2003) 3.61

HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56

Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev (2002) 3.45

The social epidemiology of substance use. Epidemiol Rev (2004) 3.41

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41

Challenges and facilitating factors in sustaining community-based participatory research partnerships: lessons learned from the Detroit, New York City and Seattle Urban Research Centers. J Urban Health (2006) 3.36

Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health (2004) 3.32

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30

Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29

Hepatitis C and progression of HIV disease. JAMA (2002) 3.15

Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep (2002) 3.14

Evaluation of an intervention to increase screening colonoscopy in an urban public hospital setting. J Urban Health (2006) 3.10

Occult hepatitis B. Lancet Infect Dis (2002) 3.09

IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02

Urban health: evidence, challenges, and directions. Annu Rev Public Health (2005) 3.02

In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00

Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99

AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med (2005) 2.97

Urban as a determinant of health. J Urban Health (2007) 2.95

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol (2006) 2.91

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71

Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64

Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61

G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61

Mental health service and medication use in New York City after the September 11, 2001, terrorist attack. Psychiatr Serv (2004) 2.58

Needlestick transmission of hepatitis C. JAMA (2002) 2.55

Cities and population health. Soc Sci Med (2005) 2.53

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45

What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J Consult Clin Psychol (2007) 2.39

Urban built environment and depression: a multilevel analysis. J Epidemiol Community Health (2005) 2.34

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34

Urban neighborhood poverty and the incidence of depression in a population-based cohort study. Ann Epidemiol (2007) 2.33

Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med (2005) 2.32

Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29

Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24

High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20

Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health (2006) 2.20

Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol (2004) 2.19

Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14

Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy (2008) 2.10

Psychological resilience after disaster: New York City in the aftermath of the September 11th terrorist attack. Psychol Sci (2006) 2.08

Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07

Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep (2007) 2.04

High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend (2002) 2.04

Primary care and health insurance among women released from New York City jails. J Health Care Poor Underserved (2006) 2.04

Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis (2007) 2.02

Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02

Income distribution and risk of fatal drug overdose in New York City neighborhoods. Drug Alcohol Depend (2003) 2.01

APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol (2004) 1.97

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis (2007) 1.96